Zobrazeno 1 - 10
of 408
pro vyhledávání: '"Mark R. Middleton"'
Autor:
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor
Externí odkaz:
https://doaj.org/article/df5ecc4526e845d49481ee6aa799d831
Autor:
Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Chrissie Butcher, Linda Collins, Caroline Haddon, Gillian Verrall, Leena Elhussein, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew S. Protheroe
Publikováno v:
BJUI Compass, Vol 4, Iss 3, Pp 322-330 (2023)
Abstract Objectives This study aimed to investigate the anti‐PD‐1 inhibitor pembrolizumab as a potential agent for use in non‐muscle‐invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run‐in study to assess the safety and tolera
Externí odkaz:
https://doaj.org/article/d7395c1210aa4beeac995f4f6e98382c
Autor:
Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang, Elizabeth Soilleux, Daniel Royston, Gabrielle Rees, Murali Kesavan, Catherine Hildyard, Farasat Kazmi, Nick La Thangue, David Kerr, Mark R. Middleton, Graham P. Collins
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refrac
Externí odkaz:
https://doaj.org/article/ed0569a0654b401a969430ba23e234a6
Autor:
Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen, Andriy Moshyk, Srividya Kotapati, Mark R. Middleton
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT01511913) in patients re
Externí odkaz:
https://doaj.org/article/99594f7922fa4fff9fddfd1d9103f9ac
Autor:
Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B. Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A. Scolyer, Pippa Corrie, David J. Adams, Alvis Brazma, Roy Rabbie
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
The identification of prognostic biomarkers can help stratify cancer patients. Here, the authors apply deep RNA sequencing from primary melanomas coupled with long-term clinical outcome data from a prospective multicentre phase III trial, to develop
Externí odkaz:
https://doaj.org/article/c4c725539da241dab371faec795d6af6
Autor:
Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and
Externí odkaz:
https://doaj.org/article/9229b82e8dee4f2dbaac9757d91d7c68
Autor:
Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B. Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A. Scolyer, Pippa Corrie, David J. Adams, Alvis Brazma, Roy Rabbie
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/2d36fe56094f405ab8536dfd8423f8a9
Autor:
Serigne N. Lo, Angela M. Hong, Lauren E. Haydu, Tasnia Ahmed, Elizabeth J. Paton, Victoria Steel, George Hruby, Anh Tran, Rachael L. Morton, Anna K. Nowak, Janette L. Vardy, Katharine J. Drummond, Haryana M. Dhillon, Catherine Mandel, Richard A. Scolyer, Mark R. Middleton, Bryan H. Burmeister, John F. Thompson, Gerald B. Fogarty
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background The WBRTMel trial is a multinational, open-label, phase III randomised controlled trial comparing whole brain radiotherapy (WBRT) to observation following local treatment of one to three melanoma brain metastases with surgery and/
Externí odkaz:
https://doaj.org/article/e7e657be5c904228af9131f9b3044cd2
Autor:
Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable sta
Externí odkaz:
https://doaj.org/article/1127b00ac05c4e56bcaae9dafbb280fc
Autor:
Paul C. Lyon, BSc, MSc, MRCS, MRes, DPhil, Helen Winter, BSc, MBBS, MSc, MRCP, FRACP, Karin Herbschleb, MRCP, Leticia Campo, Diploma, Robert Carlisle, PhD, Feng Wu, MD, PhD, Robert Goldin, MD, MEd, FRCPath, Constantin C. Coussios, PhD, Mark R. Middleton, BA, MA, PhD, FRCP, Fergus V. Gleeson, FRCR, FRCP, Philip Boardman, FRCR, Ricky A. Sharma, MB, BChir, MA, PhD, FRCP, FRCR
Publikováno v:
Radiology Case Reports, Vol 13, Iss 6, Pp 1259-1266 (2018)
Liver metastasis from breast cancer is associated with poor prognosis and is a major cause of early morbidity and mortality. When liver resection is not feasible, minimally invasive directed therapies are considered to attempt to prolong survival. Se
Externí odkaz:
https://doaj.org/article/20f6dd12649d40dc90fb887054b18b43